Mark Tarnopolsky

Dr Mark Tarnopolsky

Co-Applicant

Professor of Pediatrics and Medicine, Director of Neuromuscular and Neurometabolic Clinic, McMaster University Medical Center

CEO/CSO Exerkine Corporation


NMD4C Involvement: Pillar 1: Preclinical Science

Email Mark

Research Interests: Mitochondrial disease, Neurogenetic diagnostics, Neurometabolic disorders, MD therapeutics, Aging/sarcopenia, Obesity

Academic web profile
Google Scholar profile

Biography

Dr. Tarnopolsky is a neuromuscular and neurometabolic clinician-scientist who received an MD and PhD (Cell Biology and Metabolism) from McMaster University.  He currently holds an endowed chair from McMaster Children’s Hospital Foundation in the area of neuromuscular and neurometabolic genetic disorders and follows over 1500 patients with myopathies, mitochondrial disorders and other neurogenetic disorders. He has published over 500 peer reviewed papers and has an h-index of 142.  His research focuses on pharmacological, nutraceutical and exercise therapies for neuromuscular and neurometabolic disorders, aging, obesity and other disorders that affect the mitochondria and muscle function.  He is the founder, CEO and CSO of Exerkine Corporation which is a bio-technology/nutraceutical company developing therapies for aging, obesity, muscular dystrophy and mitochondrial disorders.


Recent Publications

Al-Mhanna, SB, Poon, ET, Franklin, BA, Tarnopolsky, MA, Hawley, JA, Jakicic, JM et al.. Comparative effectiveness of high-intensity interval training and moderate-intensity continuous training on cardiometabolic health in patients with diabesity: a systematic review and meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2025.17 (1)331 PMID:40804647

Karaa, A, Goldstein, A, Cohen, BH, Haas, RH, Vockley, J, Gorman, GS et al.. RePOWER: An International, Prospective, Non-Interventional Registry of Patients With Primary Mitochondrial Myopathy. Clin Genet. 2025. PMID:40785393

Grafham, GK, Mak, G, Grant, S, Murphy, A, Baker, SK, Tarnopolsky, M et al.. Intracellular amyloidosis in peripheral nerve and skeletal muscle. J Neuropathol Exp Neurol. 2025. PMID:40700473

Candow, DG, Ostojic, SM, Chilibeck, PD, Longobardi, I, Gualano, B, Tarnopolsky, MA et al.. Creatine monohydrate supplementation for older adults and clinical populations. J Int Soc Sports Nutr. 2025.22 (sup1)2534130 PMID:40673730

Ostojic, SM, Candow, DG, Tarnopolsky, MA. Creatine and post-viral fatigue syndrome: an update. J Int Soc Sports Nutr. 2025.22 (sup1)2517278 PMID:40481620

Nava, C, Cogne, B, Santini, A, Leitão, E, Lecoquierre, F, Chen, Y et al.. Dominant variants in major spliceosome U4 and U5 small nuclear RNA genes cause neurodevelopmental disorders through splicing disruption. Nat Genet. 2025.57 (6)1374-1388 PMID:40379786

Krag, T, Nasho, E, Brady, L, Verebi, C, Leturcq, F, Malfatti, E et al.. Variants in CAPN3 Causing Autosomal Dominant Limb-Girdle Muscular Dystrophy Combined With Calpain-3 Deficiency. Hum Mutat. 2025.2025 9301465 PMID:40226307

Tsampalieros, A, McKim, D, Barrowman, N, Bijelic, V, Mah, JK, McMillan, HJ et al.. Lung Volume Recruitment and Quality of Life in Duchenne Muscular Dystrophy: Secondary Analysis of the STEADFAST Randomized Controlled Trial. Ann Am Thorac Soc. 2025.22 (8)1193-1200 PMID:40185084

Ji, D, Mylvaganam, S, Ravi Chander, P, Tarnopolsky, M, Murphy, K, Carlen, P et al.. Mitochondria and oxidative stress in epilepsy: advances in antioxidant therapy. Front Pharmacol. 2024.15 1505867 PMID:40177125

Pentz, R, Hough, R, Li, C, Tarnopolsky, M, Jones, K, RamachandranNair, R et al.. Biallelic SCN1A variants with divergent epilepsy phenotypes. Seizure. 2025.127 88-93 PMID:40120363

See more on PubMed